{"id":"NCT00577863","sponsor":"Eli Lilly and Company","briefTitle":"Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy","officialTitle":"B3D-MC-GHDF: Community Experience of Subjects With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2008-05","completion":"2008-12","firstPosted":"2007-12-20","resultsPosted":"2009-06-24","lastUpdate":"2009-07-22"},"enrollment":200,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"teriparatide","otherNames":["LY333334"]}],"arms":[],"summary":"This study is being conducted to collect information from subjects with osteoporosis regarding their experience using the Forteo B Pen to self-administer teriparatide in the community setting. Information collected during this study will be used to assess the need for changes to the Forteo B-Pen User Manual and patient educational tools. Additionally, the information generated from patients during this trial will be reviewed to assess the acceptability of the Forteo B Pen for commercial launch.","primaryOutcome":{"measure":"Summary of Forteo B Pen Complaints at 8 Weeks","timeFrame":"8 weeks","effectByArm":[{"arm":"Forteo B Pen Users","deltaMin":47,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["19656016"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14},"commonTop":["Upper respiratory tract infection","Fatigue","Arthralgia","Nausea","Urinary tract infection"]}}